The purpose of this study is to establish the clinical superiority and the safety of topical pexiganan cream 0.8% plus standard local wound care as compared to placebo cream plus standard local wound care, in the treatment of mildly infected diabetic foot ulcers.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
200
Number of Participants With Clinical Response
The numbers of participants with Clinical Response, defined as resolution of infection, are reported.
Time frame: 28 days
Number of Participants With Microbiological Response
The numbers of participants with Microbiological Response, defined are eradication of all baseline pathogens, are reported.
Time frame: 28 days
Number of Participants With Treatment-Emergent Adverse Events (TEAE)
The number of participants with TEAEs, including Serious TEAEs, are reported
Time frame: 28 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Unnamed facility
Phoenix, Arizona, United States
Unnamed facility
Tucson, Arizona, United States
Unnamed facility
Jonesboro, Arkansas, United States
Unnamed facility
Castro Valley, California, United States
Unnamed facility
Davis, California, United States
Unnamed facility
Los Angeles, California, United States
Unnamed facility
Napa, California, United States
Unnamed facility
San Francisco, California, United States
Unnamed facility
Santa Rosa, California, United States
Unnamed facility
Sylmar, California, United States
...and 29 more locations